UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549
--------------------------------------------------------------------------------

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


Date of Report (Date of earliest event reported):      June 16, 2003
                                                      --------------------------


                         PROVECTUS PHARMACEUTICALS, INC.
               (Exact Name of Registrant as Specified in Charter)


       Nevada                          0-9410                   90-0031917
--------------------------------------------------------------------------------
(State or Other Jurisdiction of      (Commission             (I.R.S. Employer
 Incorporation or Organization)      File Number)         Identification Number)

 7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee          37931
--------------------------------------------------------------------------------
       (Address of Principal Executive Offices)               (Zip Code)

Registrant's telephone number, including area code:    865/769-4011
                                                      --------------------------

--------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)





<PAGE>



Item 5.  Other Events.

     As  previously  reported  by  Provectus  Pharmaceuticals,  Inc.,  a  Nevada
corporation  (the  "Company"),  a suit was  filed by Kelly  Adams,  on behalf of
himself  and  "as   representative   of  certain   Stockholders   of   Provectus
Pharmaceuticals,  Inc.,  a Nevada  corporation,"  on April 17, 2003 in the Third
Judicial  District Court, Salt Lake County,  Utah (the "Court").  The suit names
the Company's former  subsidiary  Provectus  Pharmaceuticals,  Inc., a Tennessee
corporation  ("PPI")  and  Michael L.  Labertew,  an attorney in Salt Lake City,
Utah,  as   defendants,   and  seeks  to  rescind  the  Agreement  and  Plan  of
Reorganization  dated April 22, 2002 by which the Company acquired PPI (with PPI
becoming a wholly owned subsidiary of the Company) and PPI's former stockholders
acquired majority ownership of our common stock.

     On June 16, 2003, the Company and its subsidiary  Xantech  Pharmaceuticals,
Inc., a Tennessee  corporation  and the successor by merger to PPI  ("Xantech"),
executed a Settlement Agreement (the "Settlement Agreement") with the plaintiff,
Mr.  Adams,  and  with  Justeene  Blankenship,   Nicholas  Julian,  and  Pacific
Management  Services,  Inc., the corporation formerly operated by Mr. Julian and
Ms.  Blankenship  ("Pacific").  Pursuant to the  Agreement,  Mr. Adams agreed to
dismiss the  litigation  pending in the Court with  prejudice and, in connection
therewith,  to file the Settlement Agreement with the Court to govern the future
relations  between the  parties.  In  addition,  the  parties to the  Settlement
Agreement   entered  into  mutual  releases  and  certain  other  covenants  and
agreements. A copy of the Settlement Agreement is filed as Exhibit 10.14 hereto.

     On June 18,  2003,  Mr.  Adams and PPI  submitted to the Court a Stipulated
Order of  Dismissal  with  Prejudice  and  Release  of Stock  Certificates  (the
"Order").  The Court entered the Order,  thereby  dismissing the litigation with
prejudice, on June 25, 2003.


Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits.


(c)  Exhibits.

     Exhibits required by Item 601 of Regulation S-B are incorporated  herein by
reference and are listed on the attached Exhibit Index, which begins on page X-1
of this Current Report on Form 8-K.





<PAGE>




                                   Signatures

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                   Provectus Pharmaceuticals, Inc.


Dated:   June 26, 2003             By:/s/ Daniel R. Hamilton
                                      ------------------------------------------
                                      Daniel R. Hamilton
                                      Chief Financial Officer

<PAGE>


                                  Exhibit Index

 Exhibit No.                      Description
--------------                    -----------

 10.14*   Settlement  Agreement  dated as of June 16,  2003 among  Kelly  Adams,
          Justeene   Blankenship,   Nichoals  Julian,   and  Pacific  Management
          Services,  Inc.;  and  Provectus  Pharmaceuticals,  Inc.  and  Xantech
          Pharmaceuticals, Inc.
----------------
      *   The  Company  agrees by this filing to  supplementally  furnish to the
          Commission,  upon request,  a copy of the exhibits and/or schedules to
          this agreement.
[{"type": "8-K", "sequence": "1", "filename": "pr8kjune26.txt", "description": "CURRENT REPORT ON FORM 8-K", "secsgml_size_bytes": 5100}]
{"company-data": {"conformed-name": "PROVECTUS PHARMACEUTICALS INC", "cik": "0000315545", "assigned-sic": "2834", "irs-number": "900031917", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-09410", "film-number": "03759249"}, "business-address": {"street1": "7327 OAK RIDGE HWY", "street2": "SUITE B", "city": "KNOXVILLE", "state": "TN", "zip": "37931", "phone": "865-769-4011"}, "mail-address": {"street1": "7327 OAK RIDGE HWY", "street2": "SUITE B", "city": "KNOXVILLE", "state": "TN", "zip": "37931"}, "former-company": [{"former-conformed-name": "ZAMAGE DIGITAL IMAGING INC", "date-changed": "20011126"}, {"former-conformed-name": "SPM GROUP INC", "date-changed": "19920703"}]}
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549
--------------------------------------------------------------------------------

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported):      June 16, 2003
                                                      --------------------------

                         PROVECTUS PHARMACEUTICALS, INC.
               (Exact Name of Registrant as Specified in Charter)

       Nevada                          0-9410                   90-0031917
--------------------------------------------------------------------------------
(State or Other Jurisdiction of      (Commission             (I.R.S. Employer
 Incorporation or Organization)      File Number)         Identification Number)

 7327 Oak Ridge Highway, Suite A, Knoxville, Tennessee          37931
--------------------------------------------------------------------------------
       (Address of Principal Executive Offices)               (Zip Code)

Registrant's telephone number, including area code:    865/769-4011
                                                      --------------------------

--------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)
Item 5.  Other Events.

     As  previously  reported  by  Provectus  Pharmaceuticals,  Inc.,  a  Nevada
corporation  (the  "Company"),  a suit was  filed by Kelly  Adams,  on behalf of
himself  and  "as   representative   of  certain   Stockholders   of   Provectus
Pharmaceuticals,  Inc.,  a Nevada  corporation,"  on April 17, 2003 in the Third
Judicial  District Court, Salt Lake County,  Utah (the "Court").  The suit names
the Company's former  subsidiary  Provectus  Pharmaceuticals,  Inc., a Tennessee
corporation  ("PPI")  and  Michael L.  Labertew,  an attorney in Salt Lake City,
Utah,  as   defendants,   and  seeks  to  rescind  the  Agreement  and  Plan  of
Reorganization  dated April 22, 2002 by which the Company acquired PPI (with PPI
becoming a wholly owned subsidiary of the Company) and PPI's former stockholders
acquired majority ownership of our common stock.

     On June 16, 2003, the Company and its subsidiary  Xantech  Pharmaceuticals,
Inc., a Tennessee  corporation  and the successor by merger to PPI  ("Xantech"),
executed a Settlement Agreement (the "Settlement Agreement") with the plaintiff,
Mr.  Adams,  and  with  Justeene  Blankenship,   Nicholas  Julian,  and  Pacific
Management  Services,  Inc., the corporation formerly operated by Mr. Julian and
Ms.  Blankenship  ("Pacific").  Pursuant to the  Agreement,  Mr. Adams agreed to
dismiss the  litigation  pending in the Court with  prejudice and, in connection
therewith,  to file the Settlement Agreement with the Court to govern the future
relations  between the  parties.  In  addition,  the  parties to the  Settlement
Agreement   entered  into  mutual  releases  and  certain  other  covenants  and
agreements. A copy of the Settlement Agreement is filed as Exhibit 10.14 hereto.

     On June 18,  2003,  Mr.  Adams and PPI  submitted to the Court a Stipulated
Order of  Dismissal  with  Prejudice  and  Release  of Stock  Certificates  (the
"Order").  The Court entered the Order,  thereby  dismissing the litigation with
prejudice, on June 25, 2003.

Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits.

(c)  Exhibits.

     Exhibits required by Item 601 of Regulation S-B are incorporated  herein by
reference and are listed on the attached Exhibit Index, which begins on page X-1
of this Current Report on Form 8-K.
Signatures

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                   Provectus Pharmaceuticals, Inc.

Dated:   June 26, 2003             By:/s/ Daniel R. Hamilton
                                      ------------------------------------------
                                      Daniel R. Hamilton
                                      Chief Financial Officer
Exhibit Index

 Exhibit No.                      Description
--------------                    -----------

 10.14*   Settlement  Agreement  dated as of June 16,  2003 among  Kelly  Adams,
          Justeene   Blankenship,   Nichoals  Julian,   and  Pacific  Management
          Services,  Inc.;  and  Provectus  Pharmaceuticals,  Inc.  and  Xantech
          Pharmaceuticals, Inc.
----------------
      *   The  Company  agrees by this filing to  supplementally  furnish to the
          Commission,  upon request,  a copy of the exhibits and/or schedules to
          this agreement.